title: Short-term effects of brimonidine/timolol and dorzolamide/timolol on ocular perfusion pressure and blood flow in glaucoma.
abstract: BACKGROUND
  To examine the comparative short-term effects of brimonidine/timolol and dorzolamide/timolol on ocular perfusion pressure and retrobulbar blood flow in patients with primary open angle glaucoma (OAG).
  
  
  METHODS
  In a prospective, randomized, double-blind, crossover study, intraocular pressure (IOP), blood pressure (BP), ocular perfusion pressure (OPP), and retrobulbar hemodynamics were assessed in 15 patients with OAG (mean age 68.1 years, eight women) with well controlled IOP. IOP was measured by Goldman applanation tonometery and color Doppler imaging was utilized to assess the retrobulbar blood vessels before and 1 month after treatment with topical brimonidine/timolol and dorzolamide/timolol. Statistical analysis was performed by Friedman two-way analysis of variance by ranks and post-hoc Wilcoxon signed rank test for multiple comparisons with Holm's sequential Bonferroni procedure. P values <0.05 were considered statistically significant.
  
  
  RESULTS
  The Friedman test and subsequent post-hoc analysis indicated that IOP, BP, OPP, and retrobulbar blood flow velocities did not significantly differ between brimonidine/timolol and dorzolamide/timolol after 1-month treatment administration in patients with OAG and well controlled IOP.
  
  
  CONCLUSIONS
  In this cohort of patients with OAG, short-term treatment with brimonidine/timolol and dorzolamide/timolol results in similar effects on OPP and retrobulbar blood flow velocities.
authors.affiliation: Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, 46202, USA.
authors.forename: Brent
authors.initials: B
authors.lastname: Siesky
authors.forename: Alon
authors.initials: A
authors.lastname: Harris
authors.forename: Rita
authors.initials: R
authors.lastname: Ehrlich
authors.forename: Louis
authors.initials: L
authors.lastname: Cantor
authors.forename: Mohammadali M
authors.initials: MM
authors.lastname: Shoja
authors.forename: Deepam
authors.initials: D
authors.lastname: Rusia
authors.forename: David A
authors.initials: DA
authors.lastname: Hollander
authors.forename: Leslie
authors.initials: L
authors.lastname: Abrams
authors.forename: Julia M
authors.initials: JM
authors.lastname: Williams
authors.forename: Yochai
authors.initials: Y
authors.lastname: Shoshani
mesh_terms: D060433:Administration, Ophthalmic; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D000068438:Brimonidine Tartrate; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004338:Drug Combinations; D005123:Eye / Q000098:blood supply; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D011810:Quinoxalines / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use*; D014065:Tonometry, Ocular
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; D011810:Quinoxalines; D013449:Sulfonamides; D013876:Thiophenes; C479140:dorzolamide-timolol combination; D000068438:Brimonidine Tartrate; D013999:Timolol